Cardiovascular effects of gastric intubation and distension in healthy humans

2008 ◽  
Vol 20 (4) ◽  
pp. 304-310 ◽  
Author(s):  
p. cantù ◽  
d. savojardo ◽  
m. v. barelli ◽  
v. buonamici ◽  
g. bertinieri ◽  
...  
2018 ◽  
Vol 108 (6) ◽  
pp. 1229-1237 ◽  
Author(s):  
Ana Rodriguez-Mateos ◽  
Timon Weber ◽  
Simon S Skene ◽  
Javier I Ottaviani ◽  
Alan Crozier ◽  
...  

ABSTRACT Background Flavanols are an important class of food bioactives that can improve vascular function even in healthy subjects. Cocoa flavanols (CFs) are composed principally of the monomer (−)-epicatechin (∼20%), with a degree of polymerisation (DP) of 1 (DP1), and oligomeric procyanidins (∼80%, DP2–10). Objective Our objective was to investigate the relative contribution of procyanidins and (−)-epicatechin to CF intake–related improvements in vascular function in healthy volunteers. Design In a randomized, controlled, double-masked, parallel-group dietary intervention trial, 45 healthy men (aged 18–35 y) consumed the following once daily for 1 mo: 1) a DP1–10 cocoa extract containing 130 mg (−)-epicatechin and 560 mg procyanidins, 2) a DP2–10 cocoa extract containing 20 mg (−)-epicatechin and 540 mg procyanidins, or 3) a control capsule, which was flavanol-free but had identical micro- and macronutrient composition. Results Consumption of DP1–10, but not of either DP2–10 or the control capsule, significantly increased flow-mediated vasodilation (primary endpoint) and the concentration of structurally related (−)-epicatechin metabolites (SREMs) in the circulatory system while decreasing pulse wave velocity and blood pressure. Total cholesterol significantly decreased after daily intake of both DP1–10 and DP2–10 as compared with the control. Conclusions CF-related improvements in vascular function are predominantly related to the intake of flavanol monomers and circulating SREMs in healthy humans but not to the more abundant procyanidins and gut microbiome–derived CF catabolites. Reduction in total cholesterol was linked to consumption of procyanidins but not necessarily to that of (−)-epicatechin. This trial was registered at clinicaltrials.gov as NCT02728466.


2010 ◽  
Vol 24 (S1) ◽  
Author(s):  
Eric C. Wong ◽  
Courtney M. Wheatley ◽  
Nicholas A. Cassuto ◽  
William T. Foxx‐Lupo ◽  
Asad E. Patanwala ◽  
...  

1964 ◽  
Vol 47 (4) ◽  
pp. 388-394 ◽  
Author(s):  
Irwin E. Vinnik ◽  
Fred Kern

VASA ◽  
2010 ◽  
Vol 39 (1) ◽  
pp. 43-53 ◽  
Author(s):  
Grotenhermen

Background: To investigate the hypothesis that cases of arteritis similar to thromboangiitis obliterans (TAO) and associated with the use of cannabis were caused by cannabis or THC (dronabinol), or that cannabis use is a co-factor of TAO. Patients and methods: A systematic review on case reports and the literature on so-called cannabis arteritis, TAO, and cardiovascular effects of cannabinoids was conducted. Results: Fifteen reports with 57 cases of an arteritis associated with the use of cannabis and two additional case series of TAO, in which some patients also used cannabis, were identified. Clinical and pathological features of cannabis-associated arteritis do not differ from TAO and the major risk factor of TAO, tobacco use, was present in most, if not in all of these cases. The proposed pathophysiological mechanisms for the development of an arteritis by cannabis use are not substantiated. Conclusions: The hypothesis of cannabis being a causative factor or co-factor of TAO or an arteritis similar to TAO is not supported by the available evidence. The use of the term “cannabis arteritis” should be avoided until or unless more convincing scientific support is forthcoming.


2003 ◽  
Vol 1 (3) ◽  
pp. 211-218 ◽  
Author(s):  
Heather J. Chial ◽  
Michael Camilleri ◽  
Irene Ferber ◽  
Silvia Delgado-Aros ◽  
Duane Burton ◽  
...  
Keyword(s):  

Sign in / Sign up

Export Citation Format

Share Document